MP06-20 Long term follow-up study of polytetrafluoroethylene (PTFE) coated self-expandable metallic urethral stents a management modality for recurrent bulbar urethral stricture

You have accessJournal of UrologyReconstruction: Urethral Reconstruction (including stricture) I (MP06)1 May 2024MP06-20 Long term follow-up study of polytetrafluoroethylene (PTFE) coated self-expandable metallic urethral stents a management modality for recurrent bulbar urethral stricture Amr Elmekresh, Abdulmunem Alsadi, Kais Kotish, Mohammad Hassan Alhamad, Yaser Saeedi, and Fariborz Bagheri Amr ElmekreshAmr Elmekresh , Abdulmunem AlsadiAbdulmunem Alsadi , Kais KotishKais Kotish , Mohammad Hassan AlhamadMohammad Hassan Alhamad , Yaser SaeediYaser Saeedi , and Fariborz BagheriFariborz Bagheri View All Author Informationhttps://doi.org/10.1097/01.JU.0001009452.79331.fd.20AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Urethral stricture is fairly common, and its management remains a therapeutic challenge for urologist. It is often acquired either from Injury or inflammation and trauma causes bulbar urethral injury, pelvic fractures can result in urethral distraction defect. Following recent advances in endoscopic and reconstructive surgery, Endoscopic internal urethrotomy is the most standard procedure for benign urethral stricture still has a 50-60% recurrence rate. While urethroplasty is leading to the higher success rate of 85 % > in experienced hands. UVENTA urethral Stent (Taewoong Medical) is a temporary self-expandable covered metallic stent. A nickel-titanium coil covered by a silicone coat with Anti-migration system and different radial force. METHODS: A retrospective observational study of 31 patients with recurrent bulbar strictures was conducted from 2017 to 2023, where they received different sized double-layered, PTFE-coated self-expanding stents (Uventa, Taewoong Medical). Uroflowmetry and ascending urethrography evaluated the strictures. Data on demographics, clinical features, previous interventions, stent time, complications, and patient satisfaction were collected and consented. Success was marked by no further procedures and normal flow rates without symptoms up to a year post-removal, then biannually. RESULTS: In a study with 27 evaluable patients, 21 (78.2%) achieved clinical success over a median of 32.3 months. Urine flow rates improved post-procedure. Of the 31 treated from 2017 to 2023, two retained the stent; complications included clotting on warfarin, thread tearing, incontinence, stent migration, and invagination leading to urinary retention. Stent removal was typically straightforward, but two cases were challenging due to incrustation; five patients experienced stricture recurrence, and the median stent duration was 5.1 months. CONCLUSIONS: In our study, the success rate of temporary urethral stent placement has remained at 78.2% at a median. Follow-up of 32.3 months. We conclude that further randomized controlled studies with number and more long-term follow up are required to fully evaluate the outcome. A four to six months span could be fair. Download PPTDownload PPT Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e60 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Amr Elmekresh More articles by this author Abdulmunem Alsadi More articles by this author Kais Kotish More articles by this author Mohammad Hassan Alhamad More articles by this author Yaser Saeedi More articles by this author Fariborz Bagheri More articles by this author Expand All Advertisement PDF downloadLoading ...